Breast cancer risks associated with missense variants in breast cancer susceptibility genes
Preprint
Abstract
BACKGROUND: Protein truncating variants in ATM, BRCA1, BRCA2, CHEK2 and PALB2 are associated with increased breast cancer risk, but risks associated with missense variants in these genes are uncertain. METHODS: Combining 59,639 breast cancer cases and 53,165 controls, we sampled training (80%) and validation (20%) sets to analyze rare missense variants in ATM (1,146 training variants), BRCA1 (644), BRCA2 (1,425), CHEK2 (325) and PALB2 (472). We evaluated breast cancer risks according to five in-silico prediction-of-deleteriousness algorithms, functional protein domain, and frequency, using logistic regression models and also mixture models in which a subset of variants was assumed to be risk-associated. RESULTS: The most predictive in-silico algorithms were Helix ( BRCA1, BRCA2 and CHEK2) and CADD ( ATM ). Increased risks appeared restricted to functional protein domains for ATM (FAT and PIK domains) and BRCA1 (RING and BRCT domains). For ATM, BRCA1 and BRCA2 , data were compatible with small subsets (approximately 7%, 2% and 0.6%, respectively) of rare missense variants giving similar risk to those of protein truncating variants in the same gene. For CHEK2 , data were more consistent with a large fraction (approximately 60%) of rare missense variants giving a lower risk (OR 1.75, 95% CI (1.47-2.08)) than CHEK2 protein truncating variants. There was little evidence for an association with risk for missense variants in PALB2 . The best fitting models were well calibrated in the validation set. CONCLUSIONS: These results will inform risk prediction models and the selection of candidate variants for functional assays, and could contribute to the clinical reporting of gene panel testing for breast cancer susceptibility.Keywords
All Related Versions
- Published version: Genome Medicine, 14 (1), 1.
This publication has 24 references indexed in Scilit:
- Growing Recognition of the Role for Rare Missense Substitutions in Breast Cancer SusceptibilityBiomarkers in Medicine, 2014
- A general framework for estimating the relative pathogenicity of human genetic variantsNature Genetics, 2014
- Rare, evolutionarily unlikely missense substitutions in CHEK2contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening studyBreast Cancer Research, 2011
- Rare, Evolutionarily Unlikely Missense Substitutions in ATM Confer Increased Risk of Breast CancerThe American Journal of Human Genetics, 2009
- Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test resultsHuman Mutation, 2008
- Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applicationsHuman Mutation, 2008
- A Systematic Genetic Assessment of 1,433 Sequence Variants of Unknown Clinical Significance in the BRCA1 and BRCA2 Breast Cancer–Predisposition GenesThe American Journal of Human Genetics, 2007
- Integrated Evaluation of DNA Sequence Variants of Unknown Clinical Significance: Application to BRCA1 and BRCA2The American Journal of Human Genetics, 2004
- Maximum Entropy Modeling of Short Sequence Motifs with Applications to RNA Splicing SignalsJournal of Computational Biology, 2004
- ATM Mutations and Phenotypes in Ataxia-Telangiectasia Families in the British Isles: Expression of Mutant ATM and the Risk of Leukemia, Lymphoma, and Breast CancerThe American Journal of Human Genetics, 1998